APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Duchenne Muscular Dystrophy (DMD)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for Duchenne Muscular Dystrophy (DMD) Industry Growth and Trends Forecast to 2032

2 January 202689 pages

Choose your research edition.

Industry ResearchDrugs for Duchenne Muscular Dystrophy (DMD) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

According to APO Research, the global Drugs for Duchenne Muscular Dystrophy (DMD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Drugs for Duchenne Muscular Dystrophy (DMD) market include Bristol-Myers Squibb, Italfarmaco, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, WaVe life Science and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for Duchenne Muscular Dystrophy (DMD) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Duchenne Muscular Dystrophy (DMD) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Duchenne Muscular Dystrophy (DMD).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Drugs for Duchenne Muscular Dystrophy (DMD) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for Duchenne Muscular Dystrophy (DMD) Market by Company

Bristol-Myers Squibb

Italfarmaco

PTC Therapeutics

Santhera Pharmaceuticals

Sarepta Therapeutics

WaVe life Science

Pfizer

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type

Eteplirsen

Deflazacort

Ataluren

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application

Home Care

Hospitals

Clinics

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Duchenne Muscular Dystrophy (DMD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Duchenne Muscular Dystrophy (DMD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Drugs for Duchenne Muscular Dystrophy (DMD) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2021-2026) Table 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2027-2032) Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2026) Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share Forecasted by Type (2027-2032) Table 11. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2026) Table 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share Forecasted by Application (2027-2032) Table 26. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends Table 37. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers Table 38. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges Table 39. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints Table 40. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Company (2021-2026) Table 42. Global Drugs for Duchenne Muscular Dystrophy (DMD) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Company Headquarters & Area Served Table 44. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company, Product Type & Application Table 45. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Drugs for Duchenne Muscular Dystrophy (DMD) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Bristol-Myers Squibb Company Information Table 49. Bristol-Myers Squibb Business Overview Table 50. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 52. Bristol-Myers Squibb Recent Development Table 53. Italfarmaco Company Information Table 54. Italfarmaco Business Overview Table 55. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 57. Italfarmaco Recent Development Table 58. PTC Therapeutics Company Information Table 59. PTC Therapeutics Business Overview Table 60. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 62. PTC Therapeutics Recent Development Table 63. Santhera Pharmaceuticals Company Information Table 64. Santhera Pharmaceuticals Business Overview Table 65. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 67. Santhera Pharmaceuticals Recent Development Table 68. Sarepta Therapeutics Company Information Table 69. Sarepta Therapeutics Business Overview Table 70. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 72. Sarepta Therapeutics Recent Development Table 73. WaVe life Science Company Information Table 74. WaVe life Science Business Overview Table 75. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 77. WaVe life Science Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 82. Pfizer Recent Development Table 83. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 84. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) & (US$ Million) Table 85. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2026) Table 86. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 87. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Country (2027-2032) Table 88. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) & (US$ Million) Table 90. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2026) Table 91. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Country (2027-2032) Table 93. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) & (US$ Million) Table 95. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2026) Table 96. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Country (2027-2032) Table 98. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) & (US$ Million) Table 100. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2026) Table 101. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Country (2027-2032) Table 103. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) & (US$ Million) Table 105. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2026) Table 106. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Country (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Drugs for Duchenne Muscular Dystrophy (DMD) Product Image Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region: 2025 VS 2032 Figure 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2021-2032) Figure 7. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Eteplirsen Image Figure 13. Global Eteplirsen Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Deflazacort Image Figure 15. Global Deflazacort Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Ataluren Image Figure 17. Global Ataluren Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type 2025 VS 2032 Figure 20. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2032) Figure 21. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2032) Figure 23. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2032) Figure 25. Home Care Image Figure 26. Global Home Care Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Hospitals Image Figure 28. Global Hospitals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Clinics Image Figure 30. Global Clinics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application 2025 VS 2032 Figure 33. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2032) Figure 34. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2032) Figure 36. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 43. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 46. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 49. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 52. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Eteplirsen
  • Deflazacort
  • Ataluren
Applications
  • Home Care
  • Hospitals
  • Clinics
Companies covered
  • Bristol-Myers Squibb
  • Italfarmaco
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • WaVe life Science
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2032)
  5. 1.4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2026)
  6. 1.4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2027-2032)
  7. 1.5 Key Regions Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  8. 1.5.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (2021-2032)
2 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Eteplirsen
  3. 2.1.2 Deflazacort
  4. 2.1.3 Ataluren
  5. 2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  6. 2.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions
  10. 2.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Type (2021-2026)
3 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Home Care
  3. 3.1.2 Hospitals
  4. 3.1.3 Clinics
  5. 3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  6. 3.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions
  10. 3.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends
  2. 4.2 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers
  3. 4.3 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges
  4. 4.4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (2021-2026)
  2. 5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Company Headquarters & Area Served
  4. 5.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company, Product Type & Application
  5. 5.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Drugs for Duchenne Muscular Dystrophy (DMD) Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Bristol-Myers Squibb
  2. 6.1.1 Bristol-Myers Squibb Company Information
  3. 6.1.2 Bristol-Myers Squibb Business Overview
  4. 6.1.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  6. 6.1.5 Bristol-Myers Squibb Recent Developments
  7. 6.2 Italfarmaco
  8. 6.2.1 Italfarmaco Company Information
  9. 6.2.2 Italfarmaco Business Overview
  10. 6.2.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  12. 6.2.5 Italfarmaco Recent Developments
  13. 6.3 PTC Therapeutics
  14. 6.3.1 PTC Therapeutics Company Information
  15. 6.3.2 PTC Therapeutics Business Overview
  16. 6.3.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  18. 6.3.5 PTC Therapeutics Recent Developments
  19. 6.4 Santhera Pharmaceuticals
  20. 6.4.1 Santhera Pharmaceuticals Company Information
  21. 6.4.2 Santhera Pharmaceuticals Business Overview
  22. 6.4.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  24. 6.4.5 Santhera Pharmaceuticals Recent Developments
  25. 6.5 Sarepta Therapeutics
  26. 6.5.1 Sarepta Therapeutics Company Information
  27. 6.5.2 Sarepta Therapeutics Business Overview
  28. 6.5.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  30. 6.5.5 Sarepta Therapeutics Recent Developments
  31. 6.6 WaVe life Science
  32. 6.6.1 WaVe life Science Company Information
  33. 6.6.2 WaVe life Science Business Overview
  34. 6.6.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  36. 6.6.5 WaVe life Science Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
7 North America
  1. 7.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  3. 7.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  3. 8.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  3. 10.3 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst